Before revision: Today, BioMotiv's subsidiary portfolio includes ten companies across five indication areas: CompanyIndicationSource InstitutionAllinaire TherapeuticsCardiologyIndiana UniversityDual TherapeuticsCancerMt.
After revision: The private biotechnology company OptiKira, which created a drug to treat retinitis pigmentosa, grew out of URLToday, BioMotiv's subsidiary portfolio includes ten companies across five indication areas: CompanyIndicationSource InstitutionAllinaire TherapeuticsCardiologyIndiana UniversityDual TherapeuticsCancerMt.